© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Discover Why the Leaders in Cell Therapy are Expanding with Title21 Health Solutions
Posted 18th February 2020

Discover Why the Leaders in Cell Therapy are Expanding with Title21 Health Solutions

Top Blood and Marrow Transplant and Immunotherapy programs depend on Title21 Health Solution’s (Title21) technology to manage the patient, product and process data from collection to infusion. We had a chance to catch up with Lynn Fischer, the CEO at Title21 who provided us with a detailed insight into the award-winning software provider.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Discover Why the Leaders in Cell Therapy are Expanding with Title21 Health Solutions
Title21

Top Blood and Marrow Transplant and Immunotherapy programs depend on Title21 Health Solution’s (Title21) technology to manage the patient, product and process data from collection to infusion. From reporting to analytics, Title21 provides all the critical data at your fingertips so the right person has the right data at the right time to make the right decisions. This allows Medical Technologists, Technical and Medical Directors to focus on higher-value work, and ultimately the patient, rather than chasing down paperwork and people.

Earlier this year, Title21 was selected as the Most Outstanding Cell Therapy Software Provider for 2019 by AI’s Global Excellence Award. We had a chance to catch up with Lynn Fischer, the CEO at Title21 who provided us with a detailed insight into the award-winning software provider.

Since their inception, Tile21’s Cloud and onpremise software manages critical patient, product and process data for cell and gene therapy, immunotherapy and regenerative medicine to ensure quality, compliance and traceability. Programs that implement Title21 solutions find they can scale more effectively to treat more patients and can also translate products more quickly and efficiently from bench to bedside, delivering the latest innovative therapies to patients faster and more safely.

Title21 has served FDA-regulated life science companies for many years with quality management software, so Title21’s experience has been of great service to the cell therapy segment. “Our technology is extremely flexible due to its configurability on the front end. That means that we can maintain a single code base while meeting each cancer center or cell manufacturers’ specific requirements.”

“Every team member at Title21 is dedicated to supporting the lifesaving work that health care providers do each and every day.”

“At Title21, we partner with the largest and top-rated cancer hospitals – placing the patient first. One of our greatest testimonials we hear often is that our customers want us to continue to solve more of their challenges with our technology. They ask Title21 to help provide solutions through technology to increase the quality, safety and efficiency of their programs.” Current Title21 customers have a strong influence on the technology roadmap to add value to patient therapeutic care and quality. Analytics and business intelligence are also important and play a significant role in the future of developing new cures and protocols more quickly and efficiently. Cell and gene therapy is a dynamic market and the protocols are changing rapidly as they are improved and refined.

Moving forward, the future looks bright for the team at Title21 as they continue to provide exceptional services and award-winning solutions to hospitals and biotech firms. “Our passion is to serve the many patients and their families who face life-threatening diseases by supporting the leading healthcare institutions and biotech companies with powerful tools that help them deliver innovative treatments to their patients. Every team member at Title21 is dedicated to supporting the lifesaving work that health care providers do each and every day” remarks Fischer.

Bringing the interview to a close, Lynn signs off by revealing the exciting plans which lie in the pipeline for the business, which includes their ambitions to further expand the business in the years to come, especially with the advancements in immunotherapy technology.

Categories: Innovation


You Might Also Like
Read Full PostRead - Eye Icon
Emerging Human-Centric Sectors: Why Mental Health and Counseling Skills Are Becoming Business Essentials
News
22/07/2025Emerging Human-Centric Sectors: Why Mental Health and Counseling Skills Are Becoming Business Essentials

In a time when strategy and innovation rule boardroom discussions, a more subdued change is occurring in all sectors: a move toward goals that are more focused on people. Businesses no longer only concentrate on technology, data, and infrastructure. They are i

Read Full PostRead - Eye Icon
Travers Smith Advises Brookfield’s Acquisition of Center Parcs UK
Legal
06/08/2015Travers Smith Advises Brookfield’s Acquisition of Center Parcs UK

Travers Smith Advises Brookfield's Acquisition of Center Parcs UK

Read Full PostRead - Eye Icon
Mid Market Top 50 – Proton Partners
Innovation
09/06/2016Mid Market Top 50 – Proton Partners

Proton Partners International Ltd is a company formed by UK based and international cancer and healthcare specialists.

Read Full PostRead - Eye Icon
The Possibilities of P2P Lending
Finance
01/07/2016The Possibilities of P2P Lending

Saving Stream is a highly innovative peer to peer investment platform launched in 2013 by Lendy Ltd. Generally speaking, peer to peer lending allows investors to finance development projects and property purchases.

Read Full PostRead - Eye Icon
The Communication Blueprint for a Seamless Merger and Acquisition
M&A
24/09/2025The Communication Blueprint for a Seamless Merger and Acquisition

Mergers and acquisitions (M&A) can be stressful for each company involved. Balance sheets must look positive, but leadership also deals with human livelihoods. Meshing two organizations means juggling people, assets and customers.

Read Full PostRead - Eye Icon
Clydesdale Bank Fined £20,678,300
Finance
15/04/2015Clydesdale Bank Fined £20,678,300

Clydesdale Bank Fined £20,678,300 for Serious Failings in PPI Complaint Handling

Read Full PostRead - Eye Icon
First Boundaries, Then Borders: Why Limits Are Your Friend When It Comes to Global Expansion
News
15/04/2026First Boundaries, Then Borders: Why Limits Are Your Friend When It Comes to Global Expansion

Organisational alignment can be an illusion of proximity, rather than an artefact of design. Within a single market, shared context and informal reinforcement create consistency in practice.

Read Full PostRead - Eye Icon
Organisational security and the hidden risk
Strategy
20/01/2021Organisational security and the hidden risk

The security needs of businesses vary greatly dependent on the sector they are in. Despite the varying requirements, each business’ broader approach to security should follow a similar format where vital assets – those that needs to be protected - are surr

Read Full PostRead - Eye Icon
How the Not-For-Profit Sector Can Embrace a Digital-First Mindset
Corporate Social Responsibility
27/06/2024How the Not-For-Profit Sector Can Embrace a Digital-First Mindset

As the not-for-profit sector stands at a pivotal juncture, the necessity of adopting a digital-first mindset cannot be overstated.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow